GlassScriptPhysician profile
Nelson Kazie
NPI 1891089744
$3,001.17
in general payments reported to CMS, 2019-2025
14 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $326 · 2021: $774 · 2022: $515 · 2023: $266 · 2024: $466 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,211.16 | 2019-2023 | Camzyos |
| Pfizer INC. | $598.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $334.66 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $134.87 | 2024 | |
| Gilead Sciences, INC. | $120.83 | 2024 | Veklury |
| Kestra Medical Technology Services, INC. | $119.62 | 2023-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.39 | 2024-2025 | Lifevest |
| Abiomed | $114.58 | 2025 | |
| Medtronic, INC. | $98.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.05 | 2023-2025 | Xifaxan |
| Abbvie INC. | $35.60 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.80 | 2024 | Jardiance |
| Baxter Healthcare | $26.42 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Kazie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.